nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Aberrant transcription factors in the cancers of the pancreas
|
Uddin, Md. Hafiz |
|
|
86 |
P2 |
p. 28-45 |
artikel |
2 |
Advancement of cancer immunotherapy using nanoparticles-based nanomedicine
|
Gowd, Vemana |
|
|
86 |
P2 |
p. 624-644 |
artikel |
3 |
Advances in biology and novel treatments of SCLC: The four-color problem in uncharted territory
|
Kashima, Jumpei |
|
|
86 |
P2 |
p. 386-395 |
artikel |
4 |
Advances in the application of nanotechnology in reducing cardiotoxicity induced by cancer chemotherapy
|
Su, Xin |
|
|
86 |
P2 |
p. 929-942 |
artikel |
5 |
Advances in the DNA Nanotechnology for the Cancer Biomarkers Analysis: Attributes and Applications
|
Xia, Ling-Ying |
|
|
86 |
P2 |
p. 1105-1119 |
artikel |
6 |
Artificial intelligence-based prediction of clinical outcome in immunotherapy and targeted therapy of lung cancer
|
Yin, Xiaomeng |
|
|
86 |
P2 |
p. 146-159 |
artikel |
7 |
Artificial intelligence in radiotherapy
|
Li, Guangqi |
|
|
86 |
P2 |
p. 160-171 |
artikel |
8 |
Association of Chlamydia and Mycoplasma infections with susceptibility to ovarian cancer: A systematic review and meta-analysis
|
Hosseininasab-nodoushan, Seyed-Abolfazl |
|
|
86 |
P2 |
p. 923-928 |
artikel |
9 |
Bacteria as a treasure house of secondary metabolites with anticancer potential
|
Mohan, Chakrabhavi Dhananjaya |
|
|
86 |
P2 |
p. 998-1013 |
artikel |
10 |
Bacteria-based immune therapies for cancer treatment
|
Howell, Lars M. |
|
|
86 |
P2 |
p. 1163-1178 |
artikel |
11 |
Benefits and limitations of nanomedicine treatment of brain cancers and age-dependent neurodegenerative disorders
|
Neganova, Margarita E. |
|
|
86 |
P2 |
p. 805-833 |
artikel |
12 |
Biomimetic approaches for targeting tumor-promoting inflammation
|
Parodi, Alessandro |
|
|
86 |
P2 |
p. 555-567 |
artikel |
13 |
Cancer depends on fatty acids for ATP production: A possible link between cancer and obesity
|
Lee, Ho |
|
|
86 |
P2 |
p. 347-357 |
artikel |
14 |
Cancer evolution: Special focus on the immune aspect of cancer
|
Hu, Xiao |
|
|
86 |
P2 |
p. 420-435 |
artikel |
15 |
Cancer immunotherapy by immune checkpoint blockade and its advanced application using bio-nanomaterials
|
Yadav, Dhananjay |
|
|
86 |
P2 |
p. 909-922 |
artikel |
16 |
Chemokine-mucinome interplay in shaping the heterogeneous tumor microenvironment of pancreatic cancer
|
Ganguly, Koelina |
|
|
86 |
P2 |
p. 511-520 |
artikel |
17 |
Chemokines and chemokine receptors in colorectal cancer; multifarious roles and clinical impact
|
Braoudaki, Maria |
|
|
86 |
P2 |
p. 436-449 |
artikel |
18 |
Chemokines and NSCLC: Emerging role in prognosis, heterogeneity, and therapeutics
|
Srivastava, Saumya |
|
|
86 |
P2 |
p. 233-246 |
artikel |
19 |
Chemokines driven ovarian cancer progression, metastasis and chemoresistance: Potential pharmacological targets for cancer therapy
|
Bose, Subhankar |
|
|
86 |
P2 |
p. 568-579 |
artikel |
20 |
Chemokines in triple-negative breast cancer heterogeneity: New challenges for clinical implications
|
Mehraj, Umar |
|
|
86 |
P2 |
p. 769-783 |
artikel |
21 |
Corrigendum to “Mitochondrial mutations and mitoepigenetics: Focus on regulation of oxidative stress-induced responses in breast cancers” [Semin. Cancer Biol. 83 (2022) 556–569]
|
Chen, Kuo |
|
|
86 |
P2 |
p. 1222 |
artikel |
22 |
Counter regulation of tumor angiogenesis by vascular endothelial growth factor and thrombospondin-1
|
Lawler, Jack |
|
|
86 |
P2 |
p. 126-135 |
artikel |
23 |
Current nano-therapeutic approaches ameliorating inflammation in cancer progression
|
Rehman, Muneeb U. |
|
|
86 |
P2 |
p. 886-908 |
artikel |
24 |
Cytokines chattering in pancreatic ductal adenocarcinoma tumor microenvironment
|
Bhatia, Rakesh |
|
|
86 |
P2 |
p. 499-510 |
artikel |
25 |
Dendrimers as nanoscale vectors: Unlocking the bars of cancer therapy
|
Dey, Asmita Deka |
|
|
86 |
P2 |
p. 396-419 |
artikel |
26 |
Dynamic impact of virome on colitis and colorectal cancer: Immunity, inflammation, prevention and treatment
|
Wang, Zhihan |
|
|
86 |
P2 |
p. 943-954 |
artikel |
27 |
Editorial Board
|
|
|
|
86 |
P2 |
p. ii |
artikel |
28 |
Emerging applications of bacteria as antitumor agents
|
Kalia, Vipin Chandra |
|
|
86 |
P2 |
p. 1014-1025 |
artikel |
29 |
Emerging perspectives on growth factor metabolic relationships in the ovarian cancer ascites environment
|
Monavarian, Mehri |
|
|
86 |
P2 |
p. 709-719 |
artikel |
30 |
Emerging role of nanoparticles in the diagnostic imaging of gastrointestinal cancer
|
Zhou, Jianfeng |
|
|
86 |
P2 |
p. 580-594 |
artikel |
31 |
Emerging trends in the application of gold nanoformulations in colon cancer diagnosis and treatment
|
Aldahhan, Razan |
|
|
86 |
P2 |
p. 1056-1065 |
artikel |
32 |
Epigenetic regulation of CXCR4 signaling in cancer pathogenesis and progression
|
Alsayed, Reem Khaled M.E. |
|
|
86 |
P2 |
p. 697-708 |
artikel |
33 |
Exosome-based nanomedicine for cancer treatment by targeting inflammatory pathways: Current status and future perspectives
|
Ansari, Mohammad Azam |
|
|
86 |
P2 |
p. 678-696 |
artikel |
34 |
Extracellular vesicles in cancer therapy
|
Wang, Shizhen Emily |
|
|
86 |
P2 |
p. 296-309 |
artikel |
35 |
Functionalized-DNA nanostructures as potential targeted drug delivery systems for cancer therapy
|
Kumar, Ajay |
|
|
86 |
P2 |
p. 54-68 |
artikel |
36 |
Green nanoparticles as multifunctional nanomedicines: Insights into anti-inflammatory effects, growth signaling and apoptosis mechanism in cancer
|
Naseer, Faiza |
|
|
86 |
P2 |
p. 310-324 |
artikel |
37 |
Gut microbes in gastrointestinal cancers
|
Wang, Fei |
|
|
86 |
P2 |
p. 967-975 |
artikel |
38 |
Helicobacters and cancer, not only gastric cancer?
|
Varon, Christine |
|
|
86 |
P2 |
p. 1138-1154 |
artikel |
39 |
Historical perspective of tumor glycolysis: A century with Otto Warburg
|
Bononi, Giulia |
|
|
86 |
P2 |
p. 325-333 |
artikel |
40 |
How far have we explored fungi to fight cancer?
|
How, Chee Wun |
|
|
86 |
P2 |
p. 976-989 |
artikel |
41 |
Immune cellular components and signaling pathways in the tumor microenvironment
|
Yenyuwadee, Sasitorn |
|
|
86 |
P2 |
p. 187-201 |
artikel |
42 |
Immune checkpoint blockade in pancreatic cancer: Trudging through the immune desert
|
Li, Xiaoqi |
|
|
86 |
P2 |
p. 14-27 |
artikel |
43 |
Immune checkpoint molecules in neuroblastoma: A clinical perspective
|
Pathania, Anup S. |
|
|
86 |
P2 |
p. 247-258 |
artikel |
44 |
Immune functions as a ligand or a receptor, cancer prognosis potential, clinical implication of VISTA in cancer immunotherapy
|
Im, Eunji |
|
|
86 |
P2 |
p. 1066-1075 |
artikel |
45 |
Impact of the ileal microbiota on colon cancer
|
Roberti, Maria Paula |
|
|
86 |
P2 |
p. 955-966 |
artikel |
46 |
Inflammation-targeted nanomedicine against brain cancer: From design strategies to future developments
|
Mamun, Abdullah Al |
|
|
86 |
P2 |
p. 101-116 |
artikel |
47 |
Inflammation targeted nanomedicines: Patents and applications in cancer therapy
|
Praveen, Thaggikuppe Krishnamurthy |
|
|
86 |
P2 |
p. 645-663 |
artikel |
48 |
Integration of chemokine signaling with non-coding RNAs in tumor microenvironment and heterogeneity in different cancers
|
Arora, Shweta |
|
|
86 |
P2 |
p. 720-736 |
artikel |
49 |
Lactate Dehydrogenase and its clinical significance in pancreatic and thoracic cancers
|
Comandatore, Annalisa |
|
|
86 |
P2 |
p. 93-100 |
artikel |
50 |
Lichens as a repository of bioactive compounds: an open window for green therapy against diverse cancers
|
Dar, Tanvir Ul Hassan |
|
|
86 |
P2 |
p. 1120-1137 |
artikel |
51 |
Mesenchymal stem/stromal cells in breast cancer development and management
|
Tu, Zhenbo |
|
|
86 |
P2 |
p. 81-92 |
artikel |
52 |
Metabolic regulation on the immune environment of glioma through gut microbiota
|
Lyu, Yingying |
|
|
86 |
P2 |
p. 990-997 |
artikel |
53 |
Microbes in gynecologic cancers: Causes or consequences and therapeutic potential
|
Wahid, Mohd |
|
|
86 |
P2 |
p. 1179-1189 |
artikel |
54 |
Microbes in lung cancer initiation, treatment, and outcome: Boon or bane?
|
Guo, Haoyue |
|
|
86 |
P2 |
p. 1190-1206 |
artikel |
55 |
Molecular subtyping of small cell lung cancer
|
Liang, Jie |
|
|
86 |
P2 |
p. 450-462 |
artikel |
56 |
Multidimensional role of bacteria in cancer: Mechanisms insight, diagnostic, preventive and therapeutic potential
|
Mughal, Muhammad Jameel |
|
|
86 |
P2 |
p. 1026-1044 |
artikel |
57 |
Multifunctional plant virus nanoparticles in the next generation of cancer immunotherapies
|
Shahgolzari, Mehdi |
|
|
86 |
P2 |
p. 1076-1085 |
artikel |
58 |
Nanomedicine for glioblastoma: Progress and future prospects
|
Khan, Imran |
|
|
86 |
P2 |
p. 172-186 |
artikel |
59 |
Nanomedicine for urologic cancers: diagnosis and management
|
Li, Chunyang |
|
|
86 |
P2 |
p. 463-475 |
artikel |
60 |
Nanomedicines: Targeting inflammatory pathway in cancer and aging
|
Sukocheva, Olga A. |
|
|
86 |
P2 |
p. 1218-1221 |
artikel |
61 |
Nanomedicines targeting the inflammasome as a promising therapeutic approach for cell senescence
|
Chaturvedi, Swati |
|
|
86 |
P2 |
p. 46-53 |
artikel |
62 |
Nanoparticle-based drug delivery systems in cancer: A focus on inflammatory pathways
|
Afshari, Amir R. |
|
|
86 |
P2 |
p. 860-872 |
artikel |
63 |
Nanoparticles: Attractive tools to treat colorectal cancer
|
Younis, Nour K. |
|
|
86 |
P2 |
p. 1-13 |
artikel |
64 |
Nano-targeting vascular remodeling in cancer: Recent developments and future directions
|
Giordo, Roberta |
|
|
86 |
P2 |
p. 784-804 |
artikel |
65 |
Natural products and their derivatives as immune check point inhibitors: Targeting cytokine/chemokine signalling in cancer
|
Gupta, Meenakshi |
|
|
86 |
P2 |
p. 214-232 |
artikel |
66 |
Neoadjuvant immunotherapy in gastrointestinal cancers – The new standard of care?
|
Petricevic, Branka |
|
|
86 |
P2 |
p. 834-850 |
artikel |
67 |
Novel therapeutic combinations with PARP inhibitors for small cell lung cancer: A bench-to-bedside review
|
Xiong, Jiaqi |
|
|
86 |
P2 |
p. 521-542 |
artikel |
68 |
Perspectives of using microRNA-loaded nanocarriers for epigenetic reprogramming of drug resistant colorectal cancers
|
Sukocheva, Olga A. |
|
|
86 |
P2 |
p. 358-375 |
artikel |
69 |
Radiation therapy-induced remodeling of the tumor immune microenvironment
|
Charpentier, Maud |
|
|
86 |
P2 |
p. 737-747 |
artikel |
70 |
Recent advances of nanodrug delivery system in the treatment of hematologic malignancies
|
Ye, Qianling |
|
|
86 |
P2 |
p. 607-623 |
artikel |
71 |
Re-establishing the comprehension of phytomedicine and nanomedicine in inflammation-mediated cancer signaling
|
Jha, Niraj Kumar |
|
|
86 |
P2 |
p. 1086-1104 |
artikel |
72 |
Regulation of pancreatic cancer therapy resistance by chemokines
|
Gautam, Shailendra K. |
|
|
86 |
P2 |
p. 69-80 |
artikel |
73 |
RNA-binding proteins and cancer metastasis
|
Wang, Shengjie |
|
|
86 |
P2 |
p. 748-768 |
artikel |
74 |
RNA-binding proteins in regulating mRNA stability and translation: roles and mechanisms in cancer
|
Li, Wei |
|
|
86 |
P2 |
p. 664-677 |
artikel |
75 |
Small cell lung cancer: Novel treatments beyond immunotherapy
|
Meijer, Job-Joris |
|
|
86 |
P2 |
p. 376-385 |
artikel |
76 |
Small cell lung cancer: Subtypes and therapeutic implications
|
Wang, Walter Z. |
|
|
86 |
P2 |
p. 543-554 |
artikel |
77 |
Small cell lung cancer transformation: From pathogenesis to treatment
|
Yin, Xiaomeng |
|
|
86 |
P2 |
p. 595-606 |
artikel |
78 |
Special issue: Therapy-induced remodeling of the tumor microenvironment
|
Pietras, Alexander |
|
|
86 |
P2 |
p. 476 |
artikel |
79 |
Targeting inflamed and non-inflamed melanomas: biological background and clinical challenges
|
Indini, Alice |
|
|
86 |
P2 |
p. 477-490 |
artikel |
80 |
Targeting matrix metalloproteinases by E3 ubiquitin ligases as a way to regulate the tumor microenvironment for cancer therapy
|
Liu, Jinxin |
|
|
86 |
P2 |
p. 259-268 |
artikel |
81 |
Targeting micro-environmental pathways by PROTACs as a therapeutic strategy
|
Liu, Jing |
|
|
86 |
P2 |
p. 269-279 |
artikel |
82 |
Targeting OXPHOS and the electron transport chain in cancer; Molecular and therapeutic implications
|
Greene, John |
|
|
86 |
P2 |
p. 851-859 |
artikel |
83 |
Targeting the tumor microenvironment of pancreatic ductal adenocarcinoma using nano-phytomedicines
|
Girish, Bala Prabhakar |
|
|
86 |
P2 |
p. 1155-1162 |
artikel |
84 |
TGF-β in developmental and fibrogenic EMTs
|
Lee, Jun Ho |
|
|
86 |
P2 |
p. 136-145 |
artikel |
85 |
The crossroads of adenosinergic pathway and epithelial-mesenchymal plasticity in cancer
|
Iser, Isabele Cristiana |
|
|
86 |
P2 |
p. 202-213 |
artikel |
86 |
The depths of PD-1 function within the tumor microenvironment beyond CD8+ T cells
|
Laba, Stephanie |
|
|
86 |
P2 |
p. 1045-1055 |
artikel |
87 |
The development and progress of nanomedicine for esophageal cancer diagnosis and treatment
|
Li, Xiaokun |
|
|
86 |
P2 |
p. 873-885 |
artikel |
88 |
The evolutionary legacy of immune checkpoint inhibitors
|
Kaushik, Itishree |
|
|
86 |
P2 |
p. 491-498 |
artikel |
89 |
The IL-1 family in tumorigenesis and antitumor immunity
|
Sun, Runzi |
|
|
86 |
P2 |
p. 280-295 |
artikel |
90 |
Unraveling tumor microenvironment of small-cell lung cancer: Implications for immunotherapy
|
Li, Tian |
|
|
86 |
P2 |
p. 117-125 |
artikel |
91 |
Virtual screening of potential anticancer drugs based on microbial products
|
Pinto, Gaspar P. |
|
|
86 |
P2 |
p. 1207-1217 |
artikel |
92 |
‘Warburg effect’ controls tumor growth, bacterial, viral infections and immunity – Genetic deconstruction and therapeutic perspectives
|
Pouysségur, J. |
|
|
86 |
P2 |
p. 334-346 |
artikel |